We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Celltrion and Teva Pharmaceutical Industries announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for CT-P6